Pharmacokinetic investigation of dose proportionality with a 24-hour controlled-release formulation of hydromorphone

BMC Clinical Pharmacology

Volumn 7, Issue , 2007, Pages

  Sathyan, Gayatri ^a   Xu, Emily ^a   Thipphawong, John ^a   Gupta, Suneel K ^a  

^a ALZA CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIHYDROMORPHINE; JURNISTA; NALTREXONE; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; BLOOD SAMPLING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; CORRELATION ANALYSIS; CROSSOVER PROCEDURE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG RESEARCH; DRUG SAFETY; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NORMAL HUMAN; OPEN STUDY; OSMOTIC PUMP; PLASMA CONCENTRATION-TIME CURVE; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; THORAX PAIN; TIME TO MAXIMUM PLASMA CONCENTRATION; VOLUNTEER;

ADULT; AREA UNDER CURVE; CHEMISTRY, PHARMACEUTICAL; CROSS-OVER STUDIES; DELAYED-ACTION PREPARATIONS; FEMALE; HUMANS; HYDROMORPHONE; MALE; MIDDLE AGED; NARCOTICS;

EID: 33847607152     PISSN: None     EISSN: 14726904     Source Type: Journal    
DOI: 10.1186/1472-6904-7-3     Document Type: Article

References (11)

1. Quigley C Wiffen P A systematic review of hydromorphone in acute and chronic pain J Pain Symptom Manage 2003 25 169-178 10.1016/ S0885-3924(02)00643-7 12590032
2. Hill HF Coda BA Tanaka A Schaffer R Multiple-dose evaluation of intravenous hydromorphone pharmacokinetics in normal human subjects Anesth Analg 1991 72 330-336 10.1213/00000539-199103000-00009 1704690
3. Vallner JJ Stewart JT Kotzan JA Kirsten EB Honigberg IL Pharmacokinetics and bioavailability of hydromorphone following intravenous and oral administration to human subjects J Clin Pharmacol 1981 21 152-156 6165742
4. Parab PV Ritschel WA Coyle DE Gregg RV Denson DD Pharmacokinetics of hydromorphone after intravenous, peroral and rectal administration to human subjects Biopharm Drug Dispos 1988 9 187-199 10.1002/ bod.2510090207 2453226
5. Murray A Hagen NA Hydromorphone J Pain Symptom Manage 2005 29 5S S57-S66 10.1016/j.jpainsymman.2005.01.007 15907647
6. Theeuwes F Elementary osmotic pump J Pharm Sci 1975 64 1987-1991 10.1002/ jps.2600641218 1510
7. Palangio M Northfelt DW Portenoy RK Brookoff D Doyle RT Jr. Dornseif BE Damask MC Dose conversion and titration with a novel, once-daily, OROS osmotic technology, extended-release hydromorphone formulation in the treatment of chronic malignant or nonmalignant pain J Pain Symptom Manage 2002 23 355-368 10.1016/S0885-3924(02)00390-1 12007754
8. Bass DM Prevo M Waxman DS Gastrointestinal safety of an extended-release nondeformable, oral dosage form (OROS®). A retrospective study Drug Saf 2002 25 1021-1033 10.2165/00002018-200225140-00004 12408733
9. Drover DR Angst MS Valle M Ramaswamy B Naidu S Stanski DR Verotta D Input characteristics and bioavailability after administration of immediate and a new extended-release formulation of hydromorphone in healthy volunteers Anesthesiology 2002 97 827-836 10.1097/ 00000542-200210000-00013 12357147
10. Summary of Product Characteristics for JURNISTA ALZA Corporation, Mountain View, CA. May 2006
11. Sathyan G Xu E Gupta S Effect of food on the pharmacokinetic profile of OROS hydromorphone [abstract] IASP Press 2005 632 Abstract 1796-P299